中國通號(688009.SH)中標2.18億元天津地鐵11號線一期工程信號系統集成採購項目
格隆匯 3 月 19日丨中國通號(688009.SH)公佈,2021年1月至2月,受節假日影響,軌道交通重要項目招標較少,公司在軌道交通市場共中標一個重要項目,為天津地鐵11號線一期工程信號系統集成採購項目,中標金額2.18億元。
以上項目中標金額總計約為人民幣2.18億元,約佔公司中國會計準則下2019年經審計營業收入的0.52%。因為上述項目跨年分期實施,對2021年當期業績影響有不確定性;如以上項目簽訂正式合同並順利實施,在項目執行期間預計對公司產生較為積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.